Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum

(2014) Alexander Colbert et al.   mAbs

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers

(2012) Eun Sil Oh et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Loss- and Gain-of-function PCSK9 Variants

(2012) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primary Hyperlipidaemia

(2011) Jimyon Kim et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

(2011) Jennifer Q. Dong et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)

(2009) Stephen J. Nicholls et al.   AMERICAN JOURNAL OF CARDIOLOGY

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

(2009) S. A. Mousavi et al.   JOURNAL OF INTERNAL MEDICINE

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

(2008) Robert J. Schmidt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PCSK9: An enigmatic protease

(2008) Dayami Lopez   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Likelihood based approaches to handling data below the quantification limit using NONMEM VI

(2008) Jae Eun Ahn et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA